Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Head and Neck Cancers
•
Radiation Oncology
Does the extent of ENE affect your recommendation for concurrent chemotherapy in HPV+ OPSCC patients planned for adjuvant RT?
Does the ENE of 1 mm or less versus >1 mm as in ECOG 3311 affect your decision?
Answer from: Radiation Oncologist at Academic Institution
I'm wary of de-escalating treatment without phase 3 data supporting that decision. So any ECE, I treat with 66 Gy and concurrent chemo.
Sign In
or
Register
to read more
19938
Related Questions
How do you approach cisplatin dosing for locally advanced head and neck SCC in HPV-positive and HPV-negative patients?
How would you approach a patient with a carotid body tumor and metastasis to the cervical lymph node?
What is the role of adjuvant RT for metastatic RCC to the thyroid resected with high-risk features?
How would the updated results of ECOG 3311 influence your adjuvant RT recommendations for HPV+ OPSCC?
How would you approach a patient treated for a stage I glottic cancer (66 Gy) 2 years prior with a biopsy proven recurrence who is declining surgery and any systemic therapy?
How do you approach postoperative radiation therapy in a patient with head and neck cancer who has high risk of recurrence in the setting of active epidermolysis bullosa?
What is your recommendation for patients who are on weight loss medications like GLP-1-based therapies while receiving chemoradiation for head and neck cancer?
How would you manage a presumed radiation induced sarcoma of the head and neck?
How do you manage a twice-recurrent mucinous adenocarcinoma of the lower eyelid with direct involvement of the lateral rectus muscle and lacrimal duct?
How are you integrating the findings from KEYNOTE-689 into daily practice?